Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
172 Leser
Artikel bewerten:
(0)

Five Things Nobel Prize Laureate Gregg Semenza Wishes Everyone Knew About Science

BALTIMORE, Dec. 3, 2019 /PRNewswire/ -- On Dec. 10, Johns Hopkins scientist Gregg Semenza will accept the 2019 Nobel Prize in Physiology or Medicine in Stockholm, Sweden - along with scientists William G. Kaelin, Jr. and Peter J. Ratcliffe - for his groundbreaking discovery of the gene that controls how cells respond to low oxygen levels.

Gregg Semenza won the 2019 Nobel Prize in Physiology or Medicine for for his groundbreaking discovery of the gene that controls how cells respond to low oxygen levels.

In the two months since the award was announced, Semenza has done scores of media interviews and lectures to audiences around the world about the implications of this work in understanding and eventually treating blood disorders, blinding eye diseases, cancer, diabetes, coronary artery disease and other conditions.

Beyond his research, here are five points Semenza, the C. Michael Armstrong Professor at the Johns Hopkins University School of Medicine, wishes more people knew about science.

Many of the best discoveries are made by young scientists: The Nobel Prizes are usually given to older scientists for discoveries they made as younger scientists. Because of this, Semenza says people may think that good science is solely the domain of older people, but great discoveries are often made by young scientists. "We often make these findings early in our careers, but it is only much later that the significance of those discoveries becomes apparent," says Semenza.

Discoveries take perseverance and collaboration: A lot of science is taking small steps forward. Big leaps are often the result of collaboration. Semenza recalls that when he and his lab identified the HIF-1 gene, which controls cells under low oxygen conditions, they initially ran into problems trying to clone the gene's DNA. Scientists clone DNA to learn more about a gene's function and other characteristics. He got help from fellow Johns Hopkins scientist Thomas Kelly who had expertise in a workaround approach: purifying the protein made by HIF-1, another way to learn more about the gene and its function in the cell.

The best research environments have mentorship and collegiality: "There are places with very smart people, and there are places where everybody is friendly. But there are few places with smart people who are almost always willing to help you. When we wrote the manuscript reporting the discovery of HIF-1, we submitted it to top-tier journals, and they did not find it to be of sufficient interest to warrant publication," says Semenza. But that didn't stop him: Semenza got help from late Johns Hopkins scientist Victor McKusick, and the paper was published in the Proceedings of the National Academy of Sciences. It has now been cited in over 6,000 scientific publications.

To advance science, invest in early education of science: "In high school, I had a biology teacher who inspired me and others to careers in scientific research by teaching us about the scientists and the scientific process that led to discoveries. She would often preface her description of a scientific discovery by saying 'when you win your Nobel Prize, I don't want you to forget that you learned that here,'" says Semenza. "We need to give more emphasis to teachers and reward them for the work that they do, which makes such a difference in the lives of so many."

Basic science research is good for the economy: "The inventions and discoveries that come out of basic research are critical for the economy, public health and treating disease earlier," says Semenza. "It is better, both for patients and for the economy, to treat diseases early rather than later, and we need more research to learn how to more effectively treat many cancers."

CONTACT: Alsy Acevedo, 410-464-6457, aaceved5@jhmi.edu

Photo - https://mma.prnewswire.com/media/1033276/Gregg_Semenza_2019_Nobel_Prize_Winner.jpg

© 2019 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.